Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2006 • ACR Convergence 2020
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Markus Rehberg¹, Clemens Giegerich¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Jeffrey R Curtis⁴, Jacques-Eric Gottenberg⁵, Andreas Schwarting⁶, Santos Castañeda⁷, Andrea Rubbert Roth⁸ and Ernest Choy⁹, ¹Sanofi, Frankfurt, Germany, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Strasbourg University Hospital, Strasbourg, France, ⁶Johannes Gutenberg University, Mainz, Germany, ⁷Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ⁸Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ⁹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…
Abstract Number: 0030 • ACR Convergence 2020
Distinct DNA Methylation Patterns of Rheumatoid Arthritis Peripheral Blood and Synovial Tissue T Cells
Rizi Ai¹, Gary Firestein², David Boyle³ and Wei Wang⁴, ¹University of California San Diego, San Diego, CA, ²University of California, San Diego, La Jolla, CA, ³UCSD, La Jolla, CA, ⁴UCSD, La Jolla
Background/Purpose: To understand the epigenetic patterns of T cells accumulated in rheumatoid arthritis (RA) synovium, we characterized DNA methylation of CD3+ T cells in peripheral…
Abstract Number: 0084 • ACR Convergence 2020
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
Natalia Cabrera¹, Vannia Valinotti², Gabriela Avila-Pedretti¹, Sonia Cabrera², Patricia Melgarejo³, Zoilo Morel⁴, Lourdes Roman², Pedro Babak⁴, Rodrigo Acosta², Romina Glitz⁴, Darwin Cordovilla⁵, Roger Rolon⁴, Magali Zanotti-Cavazzoni¹, Marco Antonio Franco Britos⁶, Marcos Vazquez², Pedro Delgadillo⁴, Isabel Acosta², María del Carmen Martinez⁴, Gabriel Elizaur⁴, María Teresa Romero⁴, Ernesto Paredes⁴, Paloma de Abreu¹ and Leticia Segovia⁷, ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Hospital de Clínicas, Asunción, Paraguay, ³Hospital IPS, Villa Rica, Paraguay, ⁴Hospital Central del Instituto de Previsión Social, Asunción, Paraguay, ⁵Instituto Nacional de Reumatología, Montevideo, Uruguay, ⁶Instituto de Previsi�n Social, Asunci�n, Central, Paraguay, ⁷Hospital del IPS, Asunción, Paraguay
Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…
Abstract Number: 0147 • ACR Convergence 2020
The Interpretation of Patient-reported Outcomes in Rheumatoid Arthritis: Do Clinical Trials Adequately Evaluate Meaningful Improvements for Patients?
Peter Taylor¹, Robin Dore², Kate Williams³, Sarah Acaster³, Jenya Antonova⁴ and Mark Genovese⁵, ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Private practice, Tustin, CA, ³Acaster Lloyd Consulting, London, United Kingdom, ⁴Gilead Sciences, Foster City, CA, ⁵Gilead Sciences, Inc., Foster City, CA
Background/Purpose: The importance of patient-relevant outcomes, such as pain, fatigue and physical functioning, has been long established in the field of rheumatoid arthritis (RA). Patient-reported…
Abstract Number: 0184 • ACR Convergence 2020
Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study
Joanna Kedra¹, Raphaèle Seror², Philippe Dieude³, Arnaud Constantin⁴, Eric Toussirot⁵, Elias Kfoury⁶, Charles Masson⁷, Divi Cornec⁸, Jean-Jacques Dubost⁹, Laurent Marguerie¹⁰, Sebastien Ottaviani¹¹, Franck Grados¹², Rakiba Belkhir¹³, Olivier Fain¹⁴, Philippe Goupille¹⁵, Christelle Sordet¹⁶, Bruno Fautrel¹⁷, Peggy Philippe¹⁸, Muriel Piperno¹⁹, Bernard Combe²⁰, Olivier Lambotte²¹, Christophe Richez²², Jeremie Sellam²³, Thomas Sené²⁴, Guillaume Denis²⁵, Thierry Lequerre²⁶, Xavier Mariette²⁷ and Gaetane Nocturne¹³, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ²Rheumatology Department, Bicetre Hospital, APHP, France, Paris, France, ³Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France, ⁴Rheumatology Department, Toulouse University Hospital, Toulouse, France, ⁵CIC biotherapies, Besançon University Hospital, Besançon, France, ⁶Hematology Department, Brive La Gaillarde Hospital, Brive la Gaillarde, France, ⁷Rheumatology Department, Angers University Hospital, Angers, France, ⁸Rheumatology Department, Brest University Hospital, Brest, France, ⁹CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁰Department of medicine, rheumatology and neurology, Hopale hospital, Berck, France, ¹¹Rheumatology Department, Bichat hospital, APHP, Paris, France, ¹²Rheumatology Department, Amiens University Hospital, Amiens, France, ¹³Rheumatology Department, Bicetre Hospital, APHP, France, Le Kremlin-Bicêtre, France, ¹⁴Internal Medicine Department, Saint-Antoine hospital, APHP, Paris, France, ¹⁵CHU Tours, department of rheumatology, Tours, France, ¹⁶Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ¹⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹⁸Rheumatology Department, Lille University Hospital, Lille, France, ¹⁹Rheumatology Department, Lyon University Hospital, Lyon, France, ²⁰University of Montpellier, Montpellier, France, ²¹Internal Medicine Department, Bicetre Hospital, APHP, Le Kremlin-Bicêtre, France, ²²Rheumatology Hospital, Pelligrin Hospital, Bordeaux University Hospital, Bordeaux, France, ²³AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ²⁴Department of internal medicine, Diaconesses-Croix Saint-Simon Hospital, Paris, France, ²⁵Hematology Department, Rochefort Hospital, Rochefort, France, ²⁶Rheumatology, University Teaching Hospital, Rouen, France, ²⁷Paris-Sud University, Rueil-Malmaison, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of non-Hodgkin B-cell lymphoma (B-cell NHL). The objectives of this work were:To study the characteristics of…
Abstract Number: 0200 • ACR Convergence 2020
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
Kunihiro Yamaoka¹, Stanley B Cohen², Naonobu Sugiyama³, Harry Shi⁴, Jose L Rivas⁵, Annette Diehl⁴ and Josef Smolen⁶, ¹Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ²Metroplex Clinical Research Center, Dallas, TX, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer SLU, Madrid, Spain, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
Abstract Number: 0216 • ACR Convergence 2020
A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Jacques-Eric Gottenberg¹, Maya Buch², Roberto Caporali³, Grace Wright⁴, Tsutomu Takeuchi⁵, Kenneth Kalunian⁶, Alena Pechonkina⁷, Ying Guo⁷, Shangbang Rao⁸, YingMeei Tan⁸, Robin Besuyen⁹ and Mark Genovese¹⁰, ¹Strasbourg University Hospital, Strasbourg, France, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁴Association of Women in Rheumatology, New York, NY, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶School of Health Sciences, University of California, La Jolla, ⁷Gilead Sciences, Inc., Foster City, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Galapagos BV, Leiden, Netherlands, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Despite effective treatments, many patients (pts) with rheumatoid arthritis (RA) have inadequate responses to biologic DMARDs (bDMARD-IR), highlighting an unmet need. It is unclear…
Abstract Number: 0233 • ACR Convergence 2020
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
C. Fernandez-Diaz¹, Santos Castañeda², Rafael Melero³, Francisco Miguel Ortiz Sanjuan⁴, Antonio Juan-Mas⁵, Carmen Carrasco Cubero⁶, Raquel Almodovar⁷, Sebastian Rodriguez-Garcia⁸, C. Aguilera-Cros⁹, Ignacio Villa¹⁰, S. Ordoñez¹¹, Enrique Raya¹², C. Ojeda¹³, Manuel Jose Moreno-Ramos¹⁴, Gema Bonilla¹⁵, Susana Romero-Yuste¹⁶, Ana Ruibal-Escribano¹⁷, Jose Luis Andreu Sanchez¹⁸, R. Exposito¹⁹, Javier Loricera²⁰, Natalia Mena-Vazquez²¹, Ana Urriticoechea²², C. Peralta²³, Luis Arboleya²⁴, Francisco Javier Narváez²⁵, O. Maiz²⁶, Julia Fernandez Melon²⁷, P Vela²⁸, Ivan Castellvi²⁹, I. Cabezas³⁰, Alejandra Lopez Robles³¹, Patricia Carreira Delgado³², Juan M. Blanco-Madrigal³³, N. Del-val-del-amo³⁴, E Salgado³⁵, B. Garcia-magallon³⁶, Cristina Hidalgo Calleja³⁷, Mireia Corbeto Lopez³⁸, A. Perez³⁹, S. Castro⁴⁰, Juan Ramón De dios⁴¹, Andrea García Valle⁴², R Lopez⁴³, Angel García Aparicio⁴⁴, EC Cervantes⁴⁵, C Gonzalez⁴⁶, N Alvarez-Rivas⁴⁷, L. Perez⁴⁸, Miguel Ángel González-Gay⁴⁹ and Ricardo Blanco⁵⁰, ¹H. Marqués de Valdecilla, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³CHU. VIgo, Vigo, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Son Llàzer University Hospital, Mallorca, Spain, ⁶H. Mérida, Mérida, Spain, ⁷Fundación Alcorcón University Hospital, Madrid, ⁸La Princesa University Hospital, Madrid, Spain, ⁹H.Virgen del Rocio, Sevilla, Spain, ¹⁰H. Torrelavega, Santander, Spain, ¹¹H. Arnau Vilanova, LLeida, Spain, ¹²San Cecilio Clinic Universitary Hospital, Granada, Spain, ¹³H. Virgen de la Macarena, Sevilla, Spain, ¹⁴Arrixaca University Hospital, Murcia, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶H Pontevedra, Coruna, Spain, ¹⁷Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁹H. Laredo, Laredo, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Hospital Regional Universitario de Málaga, Málaga, Spain, ²²Can Misses, Ibiza, Spain, ²³H. Clinico Zaragoza, Zaragoza, Spain, ²⁴H. Oviedo, Oviedo, Spain, ²⁵Hospital Bellvitge, BARCELONA, Spain, ²⁶H. Donosti, Donosti, Spain, ²⁷H. Son Espases, Mallorca, Spain, ²⁸H Alicante, Alicante, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰H. Río Ortega, Valladolid, Spain, ³¹H. León, León, ³²H. 12 de octubre, Madrid, Spain, ³³Basurto University Hospital, Bilbao, Spain, ³⁴Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁵CHU Ourense, Ourense, Spain, ³⁶H. Huesca, Zaragoza, Spain, ³⁷Hospital Universitario Salamanca, Salamanca, Spain, ³⁸Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, ³⁹H. Puerta del Mar, Cadiz, Spain, ⁴⁰H. Joan XXIII, Tarragona, Spain, ⁴¹H. Alava, Alava, Spain, ⁴²H. Palencia, Palencia, Spain, ⁴³H. Negrin, Las Palmas, Spain, ⁴⁴H. Mostoles, Madrid, Spain, ⁴⁵H. Santiago de compostela, Santiago, Spain, ⁴⁶H. Valladolid, Valladolid, Spain, ⁴⁷H. S Agustin, Aviles, Spain, ⁴⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ⁴⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: To assess the efficacy of abatacept (ABA) in Rheumatoid Arthritis (RA) patients with Interstitial Lung Disease (ILD) (RA-ILD).Methods: Observational multicenter study of RA-ILD patients…
Abstract Number: 0456 • ACR Convergence 2020
Reduced Risk of Serious Pneumococcal Infection up to 10 Years After Immunization with 7-valent Conjugated Pneumococcal Vaccine in Patients with Inflammatory Arthritis
Johanna Nagel¹, Göran Jönsson², Jan Åke Nilsson³, Chanchai Manuswin⁴, Martin Englund⁵, Tore Saxne¹, Pierre Geborek¹ and Meliha Kapetanovic¹, ¹Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ²Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ⁴Centre of Registers South, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁵Lund University, Lund, Sweden
Background/Purpose: The aim was to examine the rates of putative pneumococcal infections up to 10 years before and after administration of heptavalent conjugated pneumococcal vaccine…
Abstract Number: 0543 • ACR Convergence 2020
Exercise Among Older Adults Living with Rheumatic Disease: Physical Activity Habits and Patient Reported Outcomes
Alexis Ogdie¹, Sofia Pedro², Joshua Baker³, Kaleb Michaud⁴ and Patricia Katz⁵, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: Among patients with rheumatic disease, physical activity is important for maintaining health and improving outcomes. EULAR recommendations suggest at least 30 min of vigorous…
Abstract Number: 0741 • ACR Convergence 2020
Constitutive Inhibitor Kappa B (IκB) Kinase 2 (IKK2) Activation Induces an Inflammatory State in Fibroblast-Like Synoviocytes
Sergio Ramirez-Perez¹, Umesh Gangishetti¹, Kyle Jones¹ and Pallavi Bhattaram², ¹Department of Orthopaedics, Department of Cell Biology, Emory University School of Medicine, Atlanta, GA, ²EMORY UNIVERSITY, Atlanta, GA
Background/Purpose: Fibroblast-like synoviocytes (FLS) are key players involved in the production of inflammatory mediators that trigger joint tissue damage in inflammatory arthritis (IA). The most…
Abstract Number: 0759 • ACR Convergence 2020
Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis
Yogan Kisten¹, Alexandra Circiumaru¹, Malena Loberg-Haarhaus², Nancy Vivar², Aleksandra Antovic³, Hamed Rezaei², Erik Af Klint¹, Aase Hensvold¹ and Anca Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ²Rheumatology clinic, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Center for Rheumatology, Academic Specialist Center, Stockholm Health Region, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Ultrasound (US) imaging biomarkers in the context of Anti-Citrullinated Protein Antibody (ACPA) autoimmunity might play an important role in the very early detection of…
Abstract Number: 0776 • ACR Convergence 2020
The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives
Consuelo Romero-Sanchez¹, Juliette De Avila², Jeimmy Andrea Chaparro-Sanabria³, Philipe Chalem Choueka⁴, Juan Manuel Bello-Gualtero⁵, Alejandro Ramos-Casallas², Lorena Chila-M² and Wilson Bautista-Molano⁶, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ³Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁴Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, ⁵Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁶University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia
Background/Purpose: Early RA (eRA) patients have a significant incidence of periodontal inflammation and overweight/obesity. A similar degree of disease activity, functional disability and health-related quality…
Abstract Number: 0793 • ACR Convergence 2020
Topological Laser Capture Microscopy (LCM)-RNAseq to Map the Rheumatoid Arthritis (RA) Synovial Transcriptome
Benjamin Van Espen¹, Andrew Wilson¹, Gregory Seumois², Narayanan Perumal³, Robert Benschop⁴, Gary Firestein⁵, Nunzio Bottini⁵ and Stephanie Stanford¹, ¹University of California, San Diego, La Jolla, ²La Jolla Institute for Immunology, La Jolla, ³Eli Lilly, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of California, San Diego, La Jolla, CA
Background/Purpose: Understanding pathogenic processes in the diseased tissue in rheumatoid arthritis (RA) is a critical step to defining disease pathogenesis and identifying novel therapeutic targets.…
Abstract Number: 0809 • ACR Convergence 2020
Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study
Sergio Schwartzman¹, Shelly Kafka², Douglas Conaway³, Aaron Broadwell⁴, Shawn Black², Stephen Xu⁵, Wayne Langholff⁶ and Jeffrey R Curtis⁷, ¹Weill Cornell Medical College, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Grand Strand Regional Medical Center, Myrtle Beach, SC, ⁴Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁵Janssen Research & Development, LLC, Spring House, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is a Phase 4, prospective, noninterventional, observational, multicenter (88 sites), 3-year…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].